Severe Familial Hypertriglyceridemia in a Child with Compound Heterozygous Pathogenic APOA5 Variants: A Case Report and Therapeutic Challenge
PDF
Cite
Share
Request
Case Report
E-PUB
30 October 2025

Severe Familial Hypertriglyceridemia in a Child with Compound Heterozygous Pathogenic APOA5 Variants: A Case Report and Therapeutic Challenge

J Clin Res Pediatr Endocrinol. Published online 30 October 2025.
1. Clinical Genetics Outpatient Clinic, Mother and Child Health Care Institute of Serbia "Dr Vukan Čupić", 11070 Belgrade, Serbia
2. Department of Endocrinology, Mother and Child Health Care Institute of Serbia "Dr Vukan Čupić", 11070 Belgrade, Serbia
3. Department of Gastroenterology, Hepatology and Nutrition, Mother and Child Health Care Institute of Serbia "Dr Vukan Čupić", 11070 Belgrade, Serbia
4. Department of Pediatrics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
5. Department of Cardiology, Mother and Child Health Care Institute of Serbia “Dr Vukan Čupic”, 11070 Belgrade, Serbia
6. University of Eastern Sarajevo, Faculty of Medicine, Foča, Republic of Srpska, Bosnia and Hercegovina
No information available.
No information available
Received Date: 16.09.2025
Accepted Date: 20.10.2025
E-Pub Date: 30.10.2025
PDF
Cite
Share
Request

Abstract

Familial hypertriglyceridemia (FHTG) is a rare inherited lipid disorder that may present with severe phenotypes when caused by compound heterozygous or biallelic APOA5 variants. We report a male child diagnosed at 2.5 years of age with  severe hypertriglyceridemia, who exhibited serum triglyceride levels persistently above 10 mmol/L (≈ 885 mg/dl) despite adherence to a low-fat diet and pharmacotherapy including fibrates, omega-3 fatty acids, and statins. Representative triglycerides at presentation were 11.6 mmol/L (≈ 1029 mg/dl). During follow‑up, the patient experienced an acute abdominal pain episode with triglycerides nearing 20 mmol/L (≈ 1770 mg/dL), managed conservatively under suspicion of pancreatitisOral glucose tolerance testing showed a high-normal insulin response (peak 84.5 mIU/L, below the insulin-resistance threshold of 100–150 mIU/L), which prompted addition of metformin. Over a decade, despite normal growth and clinical well-being, biochemical control remained suboptimal. This case illustrates the clinical utility of early genetic testing in pediatric dyslipidemias and highlights limitations of traditional treatments in monogenic severe FHTG. Emerging therapies, including antisense oligonucleotides and ANGPTL3 inhibitors, may hold future promise.

Keywords:
APOA5, familial hypertriglyceridemia, pediatric dyslipidemia, compound heterozygosity, metformin, antisense oligonucleotide therapy